

115TH CONGRESS  
2D SESSION

# H. R. 6110

To amend title XVIII of the Social Security Act to provide for the review and adjustment of payments under the Medicare outpatient prospective payment system to avoid financial incentives to use opioids instead of non-opioid alternative treatments, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

JUNE 14, 2018

Mrs. WALORSKI (for herself, Ms. JUDY CHU of California, Mrs. NOEM, Mr. MARCHANT, Ms. SÁNCHEZ, Mr. BLUMENAUER, Mr. ROTHFUS, Mr. ROSKAM, Mr. MACARTHUR, and Mr. DANNY K. DAVIS of Illinois) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

---

## A BILL

To amend title XVIII of the Social Security Act to provide for the review and adjustment of payments under the Medicare outpatient prospective payment system to avoid financial incentives to use opioids instead of non-opioid alternative treatments, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Dr. Todd Graham Pain  
3 Management, Treatment, and Recovery Act of 2018”.

4 **SEC. 2. REVIEW AND ADJUSTMENT OF PAYMENTS UNDER**  
5 **THE MEDICARE OUTPATIENT PROSPECTIVE**  
6 **PAYMENT SYSTEM TO AVOID FINANCIAL IN-**  
7 **CENTIVES TO USE OPIOIDS INSTEAD OF NON-**  
8 **OPIOID ALTERNATIVE TREATMENTS.**

9 (a) **OUTPATIENT PROSPECTIVE PAYMENT SYS-**  
10 **TEM.**—Section 1833(t) of the Social Security Act (42  
11 U.S.C. 1395l(t)) is amended by adding at the end the fol-  
12 lowing new paragraph:

13 “(22) **REVIEW AND REVISIONS OF PAYMENTS**  
14 **FOR NON-OPIOID ALTERNATIVE TREATMENTS.**—

15 “(A) **IN GENERAL.**—With respect to pay-  
16 ments made under this subsection for covered  
17 OPD services (or groups of services), including  
18 covered OPD services assigned to a comprehen-  
19 sive ambulatory payment classification, the Sec-  
20 retary—

21 “(i) shall, as soon as practicable, con-  
22 duct a review (part of which may include  
23 a request for information) of payments for  
24 opioids and evidence-based non-opioid al-  
25 ternatives for pain management (including  
26 drugs and devices, nerve blocks, surgical

1 injections, and neuromodulation) with a  
2 goal of ensuring that there are not finan-  
3 cial incentives to use opioids instead of  
4 non-opioid alternatives;

5 “(ii) may, as the Secretary determines  
6 appropriate, conduct subsequent reviews of  
7 such payments; and

8 “(iii) shall consider the extent to  
9 which revisions under this subsection to  
10 such payments (such as the creation of ad-  
11 ditional groups of covered OPD services to  
12 classify separately those procedures that  
13 utilize opioids and non-opioid alternatives  
14 for pain management) would reduce pay-  
15 ment incentives to use opioids instead of  
16 non-opioid alternatives for pain manage-  
17 ment.

18 “(B) PRIORITY.—In conducting the review  
19 under clause (i) of subparagraph (A) and con-  
20 sidering revisions under clause (iii) of such sub-  
21 paragraph, the Secretary shall focus on covered  
22 OPD services (or groups of services) assigned  
23 to a comprehensive ambulatory payment classi-  
24 fication, ambulatory payment classifications  
25 that primarily include surgical services, and

1 other services determined by the Secretary  
2 which generally involve treatment for pain man-  
3 agement.

4 “(C) REVISIONS.—If the Secretary identi-  
5 fies revisions to payments pursuant to subpara-  
6 graph (A)(iii), the Secretary shall, as deter-  
7 mined appropriate, begin making such revisions  
8 for services furnished on or after January 1,  
9 2020. Revisions under the previous sentence  
10 shall be treated as adjustments for purposes of  
11 application of paragraph (9)(B).

12 “(D) RULES OF CONSTRUCTION.—Nothing  
13 in this paragraph shall be construed to preclude  
14 the Secretary—

15 “(i) from conducting a demonstration  
16 before making the revisions described in  
17 subparagraph (C); or

18 “(ii) prior to implementation of this  
19 paragraph, from changing payments under  
20 this subsection for covered OPD services  
21 (or groups of services) which include  
22 opioids or non-opioid alternatives for pain  
23 management.”.

24 (b) AMBULATORY SURGICAL CENTERS.—Section  
25 1833(i) of the Social Security Act (42 U.S.C. 1395l(i))

1 is amended by adding at the end the following new para-  
2 graph:

3 “(8) The Secretary shall conduct a similar type of  
4 review as required under paragraph (22) of section  
5 1833(t), including the second sentence of subparagraph  
6 (C) of such paragraph, to payment for services under this  
7 subsection, and make such revisions under this paragraph,  
8 in an appropriate manner (as determined by the Sec-  
9 retary).”.

10 **SEC. 3. EXPANDING ACCESS UNDER THE MEDICARE PRO-**  
11 **GRAM TO ADDICTION TREATMENT IN FEDER-**  
12 **ALLY QUALIFIED HEALTH CENTERS AND**  
13 **RURAL HEALTH CLINICS.**

14 (a) **FEDERALLY QUALIFIED HEALTH CENTERS.—**  
15 Section 1834(o) of the Social Security Act (42 U.S.C.  
16 1395m(o)) is amended by adding at the end the following  
17 new paragraph:

18 “(3) **ADDITIONAL PAYMENTS FOR CERTAIN**  
19 **FQHCS WITH PHYSICIANS OR OTHER PRACTITIONERS**  
20 **RECEIVING DATA 2000 WAIVERS.—**

21 “(A) **IN GENERAL.—**In the case of a Fed-  
22 erally qualified health center with respect to  
23 which, beginning on or after January 1, 2019,  
24 Federally qualified health center services (as  
25 defined in section 1861(aa)(3)) are furnished

1 for the treatment of opioid use disorder by a  
2 physician or practitioner who meets the require-  
3 ments described in subparagraph (C) the Sec-  
4 retary shall, subject to availability of funds  
5 under subparagraph (D), make a payment (at  
6 such time and in such manner as specified by  
7 the Secretary) to such Federally qualified  
8 health center after receiving and approving an  
9 application submitted by such Federally quali-  
10 fied health center under subparagraph (B).  
11 Such a payment shall be in an amount deter-  
12 mined by the Secretary, based on an estimate  
13 of the average costs of training for purposes of  
14 receiving a waiver described in subparagraph  
15 (C)(ii). Such a payment may be made only one  
16 time with respect to each such physician or  
17 practitioner.

18 “(B) APPLICATION.—In order to receive a  
19 payment described in subparagraph (A), a Fed-  
20 erally qualified health center shall submit to the  
21 Secretary an application for such a payment at  
22 such time, in such manner, and containing such  
23 information as specified by the Secretary. A  
24 Federally qualified health center may apply for  
25 such a payment for each physician or practi-

1           tioner described in subparagraph (A) furnishing  
2           services described in such subparagraph at such  
3           center.

4           “(C) REQUIREMENTS.—For purposes of  
5           subparagraph (A), the requirements described  
6           in this subparagraph, with respect to a physi-  
7           cian or practitioner, are the following:

8                   “(i) The physician or practitioner is  
9                   employed by or working under contract  
10                  with a Federally qualified health center de-  
11                  scribed in subparagraph (A) that submits  
12                  an application under subparagraph (B).

13                   “(ii) The physician or practitioner  
14                  first receives a waiver under section 303(g)  
15                  of the Controlled Substances Act on or  
16                  after January 1, 2019.

17           “(D) FUNDING.—For purposes of making  
18           payments under this paragraph, there are ap-  
19           propriated, out of amounts in the Treasury not  
20           otherwise appropriated, \$6,000,000, which shall  
21           remain available until expended.”.

22           (b) RURAL HEALTH CLINIC.—Section 1833 of the  
23           Social Security Act (42 U.S.C. 1395l) is amended—

1           (1) by redesignating the subsection (z) relating  
2           to medical review of spinal subluxation services as  
3           subsection (aa); and

4           (2) by adding at the end the following new sub-  
5           section:

6           “(bb) ADDITIONAL PAYMENTS FOR CERTAIN RURAL  
7           HEALTH CLINICS WITH PHYSICIANS OR PRACTITIONERS  
8           RECEIVING DATA 2000 WAIVERS.—

9           “(1) IN GENERAL.—In the case of a rural  
10          health clinic with respect to which, beginning on or  
11          after January 1, 2019, rural health clinic services  
12          (as defined in section 1861(aa)(1)) are furnished for  
13          the treatment of opioid use disorder by a physician  
14          or practitioner who meets the requirements de-  
15          scribed in paragraph (3), the Secretary shall, subject  
16          to availability of funds under paragraph (4), make  
17          a payment (at such time and in such manner as  
18          specified by the Secretary) to such rural health clinic  
19          after receiving and approving an application de-  
20          scribed in paragraph (2). Such payment shall be in  
21          an amount determined by the Secretary, based on an  
22          estimate of the average costs of training for pur-  
23          poses of receiving a waiver described in paragraph  
24          (3)(B). Such payment may be made only one time  
25          with respect to each such physician or practitioner.



1           “(2) APPLICATION.—In order to receive a pay-  
2           ment described in paragraph (1), a rural health clin-  
3           ic shall submit to the Secretary an application for  
4           such a payment at such time, in such manner, and  
5           containing such information as specified by the Sec-  
6           retary. A rural health clinic may apply for such a  
7           payment for each physician or practitioner described  
8           in paragraph (1) furnishing services described in  
9           such paragraph at such clinic.

10           “(3) REQUIREMENTS.—For purposes of para-  
11           graph (1), the requirements described in this para-  
12           graph, with respect to a physician or practitioner,  
13           are the following:

14                   “(A) The physician or practitioner is em-  
15                   ployed by or working under contract with a  
16                   rural health clinic described in paragraph (1)  
17                   that submits an application under paragraph  
18                   (2).

19                   “(B) The physician or practitioner first re-  
20                   ceives a waiver under section 303(g) of the  
21                   Controlled Substances Act on or after January  
22                   1, 2019.

23           “(4) FUNDING.—For purposes of making pay-  
24           ments under this subsection, there are appropriated,  
25           out of amounts in the Treasury not otherwise appro-

1        priated, \$2,000,000, which shall remain available  
2        until expended.”.

3    **SEC. 4. STUDYING THE AVAILABILITY OF SUPPLEMENTAL**  
4                            **BENEFITS DESIGNED TO TREAT OR PREVENT**  
5                            **SUBSTANCE USE DISORDERS UNDER MEDI-**  
6                            **CARE ADVANTAGE PLANS.**

7        (a) IN GENERAL.—Not later than 2 years after the  
8        date of the enactment of this Act, the Secretary of Health  
9        and Human Services (in this section referred to as the  
10       “Secretary”) shall submit to Congress a report on the  
11       availability of supplemental health care benefits (as de-  
12       scribed in section 1852(a)(3)(A) of the Social Security Act  
13       (42 U.S.C. 1395w–22(a)(3)(A))) designed to treat or pre-  
14       vent substance use disorders under Medicare Advantage  
15       plans offered under part C of title XVIII of such Act. Such  
16       report shall include the analysis described in subsection  
17       (c) and any differences in the availability of such benefits  
18       under specialized MA plans for special needs individuals  
19       (as defined in section 1859(b)(6) of such Act (42 U.S.C.  
20       1395w–28(b)(6))) offered to individuals entitled to med-  
21       ical assistance under title XIX of such Act and other such  
22       Medicare Advantage plans.

23       (b) CONSULTATION.—The Secretary shall develop the  
24       report described in subsection (a) in consultation with rel-  
25       evant stakeholders, including—

1 (1) individuals entitled to benefits under part A  
2 or enrolled under part B of title XVIII of the Social  
3 Security Act;

4 (2) entities who advocate on behalf of such indi-  
5 viduals;

6 (3) Medicare Advantage organizations;

7 (4) pharmacy benefit managers; and

8 (5) providers of services and suppliers (as such  
9 terms are defined in section 1861 of such Act (42  
10 U.S.C. 1395x)).

11 (c) CONTENTS.—The report described in subsection  
12 (a) shall include an analysis on the following:

13 (1) The extent to which plans described in such  
14 subsection offer supplemental health care benefits  
15 relating to coverage of—

16 (A) medication-assisted treatments for  
17 opioid use, substance use disorder counseling,  
18 peer recovery support services, or other forms  
19 of substance use disorder treatments (whether  
20 furnished in an inpatient or outpatient setting);  
21 and

22 (B) non-opioid alternatives for the treat-  
23 ment of pain.

24 (2) Challenges associated with such plans offer-  
25 ing supplemental health care benefits relating to cov-

1 erage of items and services described in subpara-  
2 graph (A) or (B) of paragraph (1).

3 (3) The impact, if any, of increasing the appli-  
4 cable rebate percentage determined under section  
5 1854(b)(1)(C) of the Social Security Act (42 U.S.C.  
6 1395w–24(b)(1)(C)) for plans offering such benefits  
7 relating to such coverage would have on the avail-  
8 ability of such benefits relating to such coverage of-  
9 fered under Medicare Advantage plans.

10 (4) Potential ways to improve upon such cov-  
11 erage or to incentivize such plans to offer additional  
12 supplemental health care benefits relating to such  
13 coverage.

14 **SEC. 5. CLINICAL PSYCHOLOGIST SERVICES MODELS**  
15 **UNDER THE CENTER FOR MEDICARE AND**  
16 **MEDICAID INNOVATION; GAO STUDY AND RE-**  
17 **PORT.**

18 (a) CMI MODELS.—Section 1115A(b)(2)(B) of the  
19 Social Security Act (42 U.S.C. 1315a(b)(2)(B)) is amend-  
20 ed by adding at the end the following new clauses:

21 “(xxv) Supporting ways to familiarize  
22 individuals with the availability of coverage  
23 under part B of title XVIII for qualified  
24 psychologist services (as defined in section  
25 1861(ii)).

1                   “(xxvi) Exploring ways to avoid un-  
2                   necessary hospitalizations or emergency de-  
3                   partment visits for mental and behavioral  
4                   health services (such as for treating de-  
5                   pression) through use of a 24-hour, 7-day  
6                   a week help line that may inform individ-  
7                   uals about the availability of treatment op-  
8                   tions, including the availability of qualified  
9                   psychologist services (as defined in section  
10                   1861(ii)).”.

11           (b) GAO STUDY AND REPORT.—Not later than 18  
12 months after the date of the enactment of this Act, the  
13 Comptroller General of the United States shall conduct  
14 a study, and submit to Congress a report, on mental and  
15 behavioral health services under the Medicare program  
16 under title XVIII of the Social Security Act, including an  
17 examination of the following:

18                   (1) Information about services furnished by  
19                   psychiatrists, clinical psychologists, and other profes-  
20                   sionals.

21                   (2) Information about ways that Medicare bene-  
22                   ficiaries familiarize themselves about the availability  
23                   of Medicare payment for qualified psychologist serv-  
24                   ices (as defined in section 1861(ii) of the Social Se-

1 security Act (42 U.S.C. 1395x(ii)) and ways that the  
2 provision of such information could be improved.

3 **SEC. 6. PAIN MANAGEMENT STUDY.**

4 (a) IN GENERAL.—Not later than 1 year after the  
5 date of enactment of this Act, the Secretary of Health and  
6 Human Services (referred to in this section as the “Sec-  
7 retary”) shall conduct a study analyzing best practices as  
8 well as payment and coverage for pain management serv-  
9 ices under title XVIII of the Social Security Act and sub-  
10 mit to the Committee on Ways and Means and the Com-  
11 mittee on Energy and Commerce of the House of Rep-  
12 resentatives and the Committee on Finance of the Senate  
13 a report containing options for revising payment to pro-  
14 viders and suppliers of services and coverage related to  
15 the use of multi-disciplinary, evidence-based, non-opioid  
16 treatments for acute and chronic pain management for in-  
17 dividuals entitled to benefits under part A or enrolled  
18 under part B of title XVIII of the Social Security Act.  
19 The Secretary shall make such report available on the  
20 public website of the Centers for Medicare & Medicaid  
21 Services.

22 (b) CONSULTATION.—In developing the report de-  
23 scribed in subsection (a), the Secretary shall consult  
24 with—

- 1           (1) relevant agencies within the Department of  
2           Health and Human Services;
- 3           (2) licensed and practicing osteopathic and  
4           allopathic physicians, behavioral health practitioners,  
5           physician assistants, nurse practitioners, dentists,  
6           pharmacists, and other providers of health services;
- 7           (3) providers and suppliers of services (as such  
8           terms are defined in section 1861 of the Social Secu-  
9           rity Act (42 U.S.C. 1395x));
- 10          (4) substance abuse and mental health profes-  
11          sional organizations;
- 12          (5) pain management professional organizations  
13          and advocacy entities, including individuals who per-  
14          sonally suffer chronic pain;
- 15          (6) medical professional organizations and med-  
16          ical specialty organizations;
- 17          (7) licensed health care providers who furnish  
18          alternative pain management services;
- 19          (8) organizations with expertise in the develop-  
20          ment of innovative medical technologies for pain  
21          management;
- 22          (9) beneficiary advocacy organizations; and
- 23          (10) other organizations with expertise in the  
24          assessment, diagnosis, treatment, and management  
25          of pain, as determined appropriate by the Secretary.

1 (c) CONTENTS.—The report described in subsection  
2 (a) shall include the following:

3 (1) An analysis of payment and coverage under  
4 title XVIII of the Social Security Act with respect  
5 to the following:

6 (A) Evidence-based treatments and tech-  
7 nologies for chronic or acute pain, including  
8 such treatments that are covered, not covered,  
9 or have limited coverage under such title.

10 (B) Evidence-based treatments and tech-  
11 nologies that monitor substance use withdrawal  
12 and prevent overdoses of opioids.

13 (C) Evidence-based treatments and tech-  
14 nologies that treat substance use disorders.

15 (D) Items and services furnished by practi-  
16 tioners through a multi-disciplinary treatment  
17 model for pain management, including the pa-  
18 tient-centered medical home.

19 (E) Medical devices, non-opioid based  
20 drugs, and other therapies (including inter-  
21 ventional and integrative pain therapies) ap-  
22 proved or cleared by the Food and Drug Ad-  
23 ministration for the treatment of pain.

24 (F) Items and services furnished to bene-  
25 ficiaries with psychiatric disorders, substance



1 use disorders, or who are at risk of suicide, or  
2 have comorbidities and require consultation or  
3 management of pain with one or more special-  
4 ists in pain management, mental health, or ad-  
5 diction treatment.

6 (2) An evaluation of the following:

7 (A) Barriers inhibiting individuals entitled  
8 to benefits under part A or enrolled under part  
9 B of such title from accessing treatments and  
10 technologies described in subparagraphs (A)  
11 through (F) of paragraph (1).

12 (B) Costs and benefits associated with po-  
13 tential expansion of coverage under such title to  
14 include items and services not covered under  
15 such title that may be used for the treatment  
16 of pain, such as acupuncture, therapeutic mas-  
17 sage, and items and services furnished by inte-  
18 grated pain management programs.

19 (C) Pain management guidance published  
20 by the Federal Government that may be rel-  
21 evant to coverage determinations or other cov-  
22 erage requirements under title XVIII of the So-  
23 cial Security Act.

24 (3) An assessment of all guidance published by  
25 the Department of Health and Human Services on

1 or after January 1, 2016, relating to the prescribing  
2 of opioids. Such assessment shall consider incor-  
3 porating into such guidance relevant elements of the  
4 “Va/DoD Clinical Practice Guideline for Opioid  
5 Therapy for Chronic Pain” published in February  
6 2017 by the Department of Veterans Affairs and  
7 Department of Defense, including adoption of ele-  
8 ments of the Department of Defense and Veterans  
9 Administration pain rating scale.

10 (4) The options described in subsection (d).

11 (5) The impact analysis described in subsection  
12 (e).

13 (d) OPTIONS.—The options described in this sub-  
14 section are, with respect to individuals entitled to benefits  
15 under part A or enrolled under part B of title XVIII of  
16 the Social Security Act, legislative and administrative op-  
17 tions for accomplishing the following:

18 (1) Improving coverage of and payment for pain  
19 management therapies without the use of opioids, in-  
20 cluding interventional pain therapies, and options to  
21 augment opioid therapy with other clinical and com-  
22plementary, integrative health services to minimize  
23 the risk of substance use disorder, including in a  
24 hospital setting.

1           (2) Improving coverage of and payment for  
2           medical devices and non-opioid based pharma-  
3           cological and non-pharmacological therapies ap-  
4           proved or cleared by the Food and Drug Administra-  
5           tion for the treatment of pain as an alternative or  
6           augment to opioid therapy.

7           (3) Improving and disseminating treatment  
8           strategies for beneficiaries with psychiatric dis-  
9           orders, substance use disorders, or who are at risk  
10          of suicide, and treatment strategies to address  
11          health disparities related to opioid use and opioid  
12          abuse treatment.

13          (4) Improving and disseminating treatment  
14          strategies for beneficiaries with comorbidities who  
15          require a consultation or comanagement of pain with  
16          one or more specialists in pain management, mental  
17          health, or addiction treatment, including in a hos-  
18          pital setting.

19          (5) Educating providers on risks of coadminis-  
20          tration of opioids and other drugs, particularly  
21          benzodiazepines.

22          (6) Ensuring appropriate case management for  
23          beneficiaries who transition between inpatient and  
24          outpatient hospital settings, or between opioid ther-

1        apy to non-opioid therapy, which may include the  
2        use of care transition plans.

3            (7) Expanding outreach activities designed to  
4        educate providers of services and suppliers under the  
5        Medicare program and individuals entitled to bene-  
6        fits under part A or under part B of such title on  
7        alternative, non-opioid therapies to manage and  
8        treat acute and chronic pain.

9            (8) Creating a beneficiary education tool on al-  
10        ternatives to opioids for chronic pain management.

11        (e) **IMPACT ANALYSIS.**—The impact analysis de-  
12        scribed in this subsection consists of an analysis of any  
13        potential effects implementing the options described in  
14        subsection (d) would have—

15            (1) on expenditures under the Medicare pro-  
16        gram; and

17            (2) on preventing or reducing opioid addiction  
18        for individuals receiving benefits under the Medicare  
19        program.

1 **SEC. 7. SUSPENSION OF PAYMENTS BY MEDICARE PRE-**  
2 **SCRIPTION DRUG PLANS AND MA-PD PLANS**  
3 **PENDING INVESTIGATIONS OF CREDIBLE AL-**  
4 **LEGATIONS OF FRAUD BY PHARMACIES.**

5 (a) IN GENERAL.—Section 1860D–12(b) of the So-  
6 cial Security Act (42 U.S.C. 1395w–112(b)) is amended  
7 by adding at the end the following new paragraph:

8 “(7) SUSPENSION OF PAYMENTS PENDING IN-  
9 VESTIGATION OF CREDIBLE ALLEGATIONS OF FRAUD  
10 BY PHARMACIES.—

11 “(A) IN GENERAL.—The provisions of sec-  
12 tion 1862(o) shall apply with respect to a PDP  
13 sponsor with a contract under this part, a phar-  
14 macy, and payments to such pharmacy under  
15 this part in the same manner as such provisions  
16 apply with respect to the Secretary, a provider  
17 of services or supplier, and payments to such  
18 provider of services or supplier under this title.

19 “(B) RULE OF CONSTRUCTION.—Nothing  
20 in this paragraph shall be construed as limiting  
21 the authority of a PDP sponsor to conduct  
22 postpayment review.”.

23 (b) APPLICATION TO MA-PD PLANS.—Section  
24 1857(f)(3) of the Social Security Act (42 U.S.C. 1395w–  
25 27(f)(3)) is amended by adding at the end the following  
26 new subparagraph:

1                   “(D) SUSPENSION OF PAYMENTS PENDING  
2                   INVESTIGATION OF CREDIBLE ALLEGATIONS OF  
3                   FRAUD BY PHARMACIES.—Section 1860D–  
4                   12(b)(7).”.

5           (c) CONFORMING AMENDMENT.—Section 1862(o)(3)  
6 of the Social Security Act (42 U.S.C. 1395y(o)(3)) is  
7 amended by inserting “, section 1860D–12(b)(7) (includ-  
8 ing as applied pursuant to section 1857(f)(3)(D)),” after  
9 “this subsection”.

10          (d) CLARIFICATION RELATING TO CREDIBLE ALLE-  
11 GATION OF FRAUD.—Section 1862(o) of the Social Secu-  
12 rity Act (42 U.S.C. 1395y(o)) is amended by adding at  
13 the end the following new paragraph:

14                   “(4) CREDIBLE ALLEGATION OF FRAUD.—In  
15 carrying out this subsection, section 1860D–  
16 12(b)(7) (including as applied pursuant to section  
17 1857(f)(3)(D)), and section 1903(i)(2)(C), a fraud  
18 hotline tip (as defined by the Secretary) without fur-  
19 ther evidence shall not be treated as sufficient evi-  
20 dence for a credible allegation of fraud.”.

21          (e) EFFECTIVE DATE.—The amendments made by  
22 this section shall apply with respect to plan years begin-  
23 ning on or after January 1, 2020.

○